期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

消化道肿瘤靶向治疗进展 被引量：2

Development of targeted therapy on gastroeternaral tumor
下载PDF
导出
摘要 分子靶向治疗药物是近年来肿瘤治疗发展最热点的研究领域,以低毒高效的特点逐步成为临床肿瘤治疗的重要部分,目前大量的临床试验集中于研究该类药物的疗效和毒副反应。本文综述了消化道分子靶向治疗药物的最新研究进展。 Now the targeted therapeutic drugs have become the hottest field in many kinds of cancer and appear to have the advantages of low toxicity and high efficiency. There are a lot of clinical trials on the efficiency and the side effects. This article focuses on the latest advances of the targeted drugs on digestive tract cancers.
作者 王杰军
机构地区 第二军医大学附属长征医院肿瘤科
出处 《中国癌症杂志》 CAS CSCD 2007年第1期14-17,共4页 China Oncology
关键词 靶向治疗 CETUXIMAB PANITUMUMAB GEFITINIB VEGF EGFR BEVACIZUMAB semaxinib targeted therapy cetwcimab panitumumab gefitinib VEGF EGFR beacizumab semaxinib
分类号 R730.54 [医药卫生—肿瘤] R735 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Lenz HJ, Van Cutsem E, Khambata-Ford S, Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectalcarcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[J]. J Clin Oncol. 2006,24(30) :4914-4921.
  • 2Gebbia V, Del Prete S, Borsellino N, et al. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience [J]. Clin Colorectal Cancer. , 2006,5 (6):422-428.
  • 3Gibson TB, Ranganathan A, Grothey A. Randomized phase Ⅲ trim results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer[J]. Clin Colorectal Cancer. 2006,6(1):29-31.
  • 4Kuo T, Cho CD, Halsey J, hase Ⅱ study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer[J]. J Clin Oncol,2005,23(24):5613-5619.
  • 5Townsley CA, Major P, Siu LL, Phase Ⅱ study of erlotinib (OSI-774) in patients with metastatic colorectal cancer[J]. Br J Cancer,2006,94 (8): 1136-1143.
  • 6Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase Ⅱ trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 [J]. J Clin Oncol,2006,24 (30) :4922 -4927.
  • 7Chen HX, Mooney M, Boron M, Phase Ⅱ multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 [J]. J Clin Oncol, 2006,24 (21): 3354-3360.
  • 8Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase Ⅱ study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol ,2006,24 (12): 1898-1903.
  • 9Lockhart AC, Cropp GF, Berlin JD, Phase Ⅰ/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-Fu/LV (IFL) in patients with metastatic colorectal cancer[J].Am J Clin Oncol,2006,29(2) :109-115.
  • 10Hoff PM, Wolff RA, Bogaard K,et al. A Phase Ⅰ study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma [J]. Jpn J Clin Oncol,2006,36 (2): 100-103.

同被引文献42

引证文献2

二级引证文献9

中国癌症杂志
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部